Renal injury phenotypes with ICI–VEGFR-TKI combinations in renal cell carcinoma: active-comparator analyses in FAERS and JADER
BackgroundRenal adverse-event reports during immune checkpoint inhibitor (ICI)–VEGFR tyrosine kinase inhibitor (TKI) therapy may combine immune-interstitial, proteinuric, and nonspecific acute kidney injury (AKI) features. We compared their reporting p…